EAM
IMMU

Eventide Asset Management’s Immunomedics Inc IMMU Stock Holding History

Eventide Asset Management’s Portfolio IMMU Stock Details IMMU Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q3 		– Sell
-966,000
Closed -$13.4M – 137
2019
Q2 		$13.4M Sell
966,000
-446,000
-32% -$6.71M 0.41% 74
2019
Q1 		$27.1M Hold
1,412,000
– – 0.93% 35
2018
Q4 		$20.1M Buy
1,412,000
+713,000
+102% +$14.2M 0.89% 39
2018
Q3 		$14.6M Hold
699,000
– – 0.53% 63
2018
Q2 		$16.5M Buy
+699,000
New +$14M 0.69% 56

Other funds holding IMMU

ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
ACH
ArrowMark Colorado Holdings Denver, Colorado $3.76B AUM 21.77% 1-Year Est. Return
RM
RP Management New York $139M AUM 37.98% 1-Year Est. Return

Eventide Asset Management's IMMU Position: Q3 2019 in Review

Eventide Asset Management sold out of Immunomedics Inc (IMMU) in Q3 2019, closing a stake of 966,000 shares — an estimated $13.4M sold.

Eventide Asset Management first reported a position in IMMU in Q2 2018 and held it in 5 quarters. The position peaked at $27.1M in Q1 2019. 208 funds tracked by Wall St. Rank hold IMMU as of Q3 2019.

  • Eventide Asset Management reported no remaining Immunomedics Inc position as of Q3 2019 after selling out during the quarter.
  • Eventide Asset Management sold 966,000 Immunomedics Inc shares in Q3 2019, an estimated $13.4M.
  • Eventide Asset Management first reported a position in Immunomedics Inc in Q2 2018 and held it in 5 quarters.
  • Eventide Asset Management's Immunomedics Inc position peaked at $27.1M in Q1 2019.
  • 208 funds tracked by Wall St. Rank held Immunomedics Inc as of Q3 2019.

Based on Eventide Asset Management's 13F filing for Q3 2019, filed 21 Nov 2019.